Chapters Transcript Video Ben Schlechter, MD Presents Details on the Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Solid Tumors Back to Symposium A phase I/II Trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in response or refractory solid tumors. So this trial takes a T. Cell and autologous T cell derived from a patient and engineers a co receptor to buy into her to the T. Cell receptor activity is natives normal. But the cell is sort of forced into the environment of the cancer and stuck to the tumor through a co receptor process so that the T cell the immune cell sets off its own immune process and generates its own native anticancer response. And we're just sort of engineering in getting it there and then maintaining that response as opposed to setting off the response directly. This can generate an anti cancer effect on a market that's present in normal tissue without generating anti inflammatory pro inflammatory effect a normal tissue in autoimmune effect. Because hopefully the T cells that are bound to the cancer can find that difference and generate proper immune response. Whereas the T cells that are bound to normal tissue hopefully realize that normal tissue don't set off ketamine responses to the normal interaction between the T. Cell and anything else um is active and as a result to regulate it. And that's the difference between this cell and a conventional car T. We've seen two important things. Um First nobody on the clinical trials so far has had an off target effect. So the T cells are present all over the body and the present on the cancer as well as normal tissue. But they're not attacking normal tissue that's really really important that we have not seen off target inflammation even though the T cells are there. But number two as we have escalated the dose, we've begun to see responses. So we present in our poster, a patient with refractory gastroesophageal cancer, Which is her two positive who has developed a response against the cancer at 29 days. And so it's an early response and that's a significant response. These are um situations where frankly therapeutic options are limited and this is a great um finding and hopefully it really is the beginning of a broader response in her two positive cancers. Published September 23, 2022 Created by Related Presenters Benjamin L. Schlechter, MD Medical Oncology View full profile
